HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)
CUSIP: 40637H109
Q4 2017 13F Holders as of 31 Dec 2017
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 123,650,000
- Total 13F shares
- 122,499,248
- Share change
- +905,481
- Total reported value
- $2,482,081,024
- Put/Call ratio
- 48%
- Price per share
- $20.26
- Number of holders
- 196
- Value change
- +$20,859,736
- Number of buys
- 106
- Number of sells
- 67
Quarterly Holders Quick Answers
What is CUSIP 40637H109?
CUSIP 40637H109 identifies HALO - HALOZYME THERAPEUTICS, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 40637H109:
Top shareholders of HALO - HALOZYME THERAPEUTICS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Third Security, LLC |
13F
|
Company |
14%
|
17,592,771
|
$305,586,000 | — | 30 Sep 2017 | |
| BlackRock Finance, Inc. |
13F
|
Company |
9.8%
|
12,164,375
|
$211,295,000 | — | 30 Sep 2017 | |
| IRIDIAN ASSET MANAGEMENT LLC/CT |
13F
|
Company |
8.1%
|
10,005,952
|
$173,803,000 | — | 30 Sep 2017 | |
| VANGUARD GROUP INC |
13F
|
Company |
8.1%
|
9,991,405
|
$173,550,000 | — | 30 Sep 2017 | |
| BB BIOTECH AG |
13F
|
Company |
7%
|
8,626,051
|
$149,835,000 | — | 30 Sep 2017 | |
| First Eagle Investment Management, LLC |
13F
|
Company |
5.2%
|
6,444,981
|
$111,949,000 | — | 30 Sep 2017 | |
| FMR LLC |
13F
|
Company |
4%
|
4,968,581
|
$86,304,000 | — | 30 Sep 2017 | |
| Invesco Ltd. |
13F
|
Company |
3.6%
|
4,426,226
|
$76,883,000 | — | 30 Sep 2017 | |
| SENZAR ASSET MANAGEMENT, LLC |
13F
|
Company |
3.1%
|
3,830,190
|
$66,531,000 | — | 30 Sep 2017 | |
| STATE STREET CORP |
13F
|
Company |
3%
|
3,678,698
|
$63,900,000 | — | 30 Sep 2017 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
2.3%
|
2,868,670
|
$49,915,000 | — | 30 Sep 2017 | |
| SNYDER CAPITAL MANAGEMENT L P |
13F
|
Company |
2%
|
2,466,684
|
$42,846,000 | — | 30 Sep 2017 | |
| MSD Partners, L.P. |
13F
|
Company |
1.8%
|
2,245,000
|
$38,996,000 | — | 30 Sep 2017 | |
| Bank of New York Mellon Corp |
13F
|
Company |
1.7%
|
2,099,163
|
$36,462,000 | — | 30 Sep 2017 | |
| PICTET ASSET MANAGEMENT LTD |
13F
|
Company |
1.5%
|
1,888,426
|
$32,802,000 | — | 30 Sep 2017 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.4%
|
1,710,107
|
$29,704,000 | — | 30 Sep 2017 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
1.3%
|
1,581,424
|
$27,469,000 | — | 30 Sep 2017 | |
| Artisan Partners Limited Partnership |
13F
|
Company |
1.2%
|
1,435,886
|
$24,941,000 | — | 30 Sep 2017 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.93%
|
1,153,116
|
$20,028,000 | — | 30 Sep 2017 | |
| OppenheimerFunds, Inc. |
13F
|
Company |
0.81%
|
1,002,493
|
$17,413,000 | — | 30 Sep 2017 | |
| NORGES BANK |
13F
|
Company |
0.8%
|
995,008
|
$17,283,000 | — | 30 Sep 2017 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.69%
|
856,579
|
$14,879,000 | — | 30 Sep 2017 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.69%
|
856,575
|
$14,879,000 | — | 30 Sep 2017 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.68%
|
840,284
|
$14,596,000 | — | 30 Sep 2017 | |
| Granite Investment Partners, LLC |
13F
|
Company |
0.66%
|
818,505
|
$14,217,000 | — | 30 Sep 2017 | |
| Rubric Capital Management LP |
13F
|
Company |
0.63%
|
783,000
|
$13,601,000 | — | 30 Sep 2017 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.63%
|
781,691
|
$13,578,000 | — | 30 Sep 2017 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.6%
|
741,437
|
$12,879,000 | — | 30 Sep 2017 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.51%
|
635,468
|
$11,035,000 | — | 30 Sep 2017 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.47%
|
583,221
|
$10,131,000 | — | 30 Sep 2017 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.46%
|
570,513
|
$9,910,000 | — | 30 Sep 2017 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.46%
|
565,529
|
$9,823,000 | — | 30 Sep 2017 | |
| MORGAN STANLEY |
13F
|
Company |
0.45%
|
560,868
|
$9,742,000 | — | 30 Sep 2017 | |
| MACQUARIE GROUP LTD |
13F
|
Company |
0.4%
|
500,000
|
$8,685,000 | — | 30 Sep 2017 | |
| First Light Asset Management, LLC |
13F
|
Company |
0.36%
|
445,846
|
$7,744,000 | — | 30 Sep 2017 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.36%
|
445,769
|
$7,743,000 | — | 30 Sep 2017 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.31%
|
377,356
|
$6,555,000 | — | 30 Sep 2017 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
0.3%
|
365,394
|
$6,347,000 | — | 30 Sep 2017 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.28%
|
350,000
|
$6,080,000 | — | 30 Sep 2017 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.26%
|
323,388
|
$5,618,000 | — | 30 Sep 2017 | |
| SEI INVESTMENTS CO |
13F
|
Company |
0.26%
|
322,262
|
$5,598,000 | — | 30 Sep 2017 | |
| TIAA CREF INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.25%
|
315,162
|
$5,474,000 | — | 30 Sep 2017 | |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC |
13F
|
Company |
0.23%
|
282,633
|
$4,907,000 | — | 30 Sep 2017 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.22%
|
275,939
|
$4,793,000 | — | 30 Sep 2017 | |
| CREDIT SUISSE AG/ |
13F
|
Company |
0.22%
|
275,458
|
$4,784,000 | — | 30 Sep 2017 | |
| State of New Jersey Common Pension Fund D |
13F
|
Company |
0.21%
|
255,000
|
$4,429,000 | — | 30 Sep 2017 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.2%
|
250,000
|
$4,343,000 | — | 30 Sep 2017 | |
| CASTLEARK MANAGEMENT LLC |
13F
|
Company |
0.19%
|
232,905
|
$4,046,000 | — | 30 Sep 2017 | |
| TEACHERS ADVISORS, LLC |
13F
|
Company |
0.18%
|
221,194
|
$3,842,000 | — | 30 Sep 2017 | |
| GUGGENHEIM CAPITAL LLC |
13F
|
Company |
0.17%
|
213,429
|
$3,707,000 | — | 30 Sep 2017 |
Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q4 2017
As of 31 Dec 2017,
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by
196 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
122,499,248 shares.
The largest 10 holders included
Third Security, LLC, BlackRock Inc., Vanguard Group Inc, IRIDIAN ASSET MANAGEMENT LLC/CT, BB BIOTECH AG, First Eagle Investment Management, LLC, Invesco Ltd., STATE STREET CORP, FMR LLC, and JPMORGAN CHASE & CO.
This page lists
196
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2017 vs Q3 2017 Across Filers
Q3 2017 holders
164
Q4 2017 holders
196
Holder diff
32
| Investor | Q3 2017 Shares | Q4 2017 Shares | Share Diff | Share Chg % | Q3 2017 Value $ | Q4 2017 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.